{
  "ticker": "JNJ",
  "target_date": "2025-07-04",
  "actual_date": "2025-07-03",
  "collected_at": "2025-12-08T11:58:31.150528",
  "price": {
    "open": 153.32,
    "high": 154.16,
    "low": 152.78,
    "close": 153.89610290527344,
    "volume": 3482500,
    "change_1d_pct": 0.29,
    "change_7d_pct": 2.51,
    "change_30d_pct": 2.4
  },
  "technicals": {
    "rsi_14": 47.87,
    "sma_20": 151.81,
    "sma_50": 151.12,
    "macd": 0.38,
    "macd_signal": 0.099,
    "macd_histogram": 0.282,
    "bb_upper": 156.13,
    "bb_lower": 147.5,
    "price_vs_sma20_pct": 1.37,
    "price_vs_sma50_pct": 1.84,
    "volume_ratio": 0.44
  },
  "fundamentals": {
    "market_cap": 489327853568,
    "pe_ratio": 19.604248,
    "forward_pe": 19.160378,
    "price_to_book": 6.1644464,
    "price_to_sales": 5.310181,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.27,
    "pct_from_52w_low": 44.37
  },
  "macro": {
    "spy": {
      "price": 623.61,
      "change_1d_pct": 0.79,
      "change_7d_pct": 3.0
    },
    "vix": {
      "level": 16.38,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.35
    },
    "dollar_index": {
      "level": 97.18
    },
    "gold": {
      "price": 3332.5
    },
    "regime": "BULL_LOW_VOL"
  },
  "news": [
    {
      "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
      "source": "Yahoo",
      "datetime": 1751634003,
      "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
      "url": "https://finnhub.io/api/news?id=38de75c6321a7182157b434deea79fc2c84c57e99758af2c5f6aee15a535d3d1"
    },
    {
      "headline": "Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and ",
      "source": "Finnhub",
      "datetime": 1751620400,
      "summary": "an aggressive and currently incurable disease sta...",
      "url": "https://finnhub.io/api/news?id=ae8f88f6e4d750c7ed5e99748e19c15f01659f0fd9aa974e2c7f502d37eedaaa"
    },
    {
      "headline": "North America Beta-Glucan Market Forecast and Company Analysis Report 2025-2033 Featuring Koninklijke Philips, EDAP TMS, Johnson & Johnson, Medtronic, Hitachi, Theraclion, Stryker, and GE",
      "source": "Yahoo",
      "datetime": 1751617140,
      "summary": "The North America Beta Glucan Market, valued at USD 204.03 million in 2024, is poised to grow to USD 373.85 million by 2033, with a CAGR of 6.96% from 2025 to 2033. This growth is driven by rising consumer demand for immune-boosting and functional food ingredients and increased awareness of beta glu",
      "url": "https://finnhub.io/api/news?id=9a695f3816acc6952f8e0f678e70f27b0d26658dc6967d150502d81d85dce021"
    },
    {
      "headline": "Goldman Sachs Rates Johnson & Johnson a Buy, Citing Pipeline Strength and Policy Tailwinds",
      "source": "Yahoo",
      "datetime": 1751613777,
      "summary": "Johnson & Johnson (NYSE:JNJ) ranks among the best set-it-and-forget-it stocks to buy. Asad Haider, a Goldman Sachs analyst, remained optimistic about Johnson & Johnson (NYSE:JNJ) shares, rating it as a Buy on June 5. The analyst noted several factors that lead to the update. Similar to its industry ",
      "url": "https://finnhub.io/api/news?id=83c2fd7de6b6ab3b7767f478e9ec57201c39d0fbdd714e21a342c52456c8b956"
    },
    {
      "headline": "NYLI Balanced Fund Q1 2025 Commentary",
      "source": "SeekingAlpha",
      "datetime": 1751586300,
      "summary": "The NYLI Balanced Fund outperformed its benchmark only marginally this quarter but landed solidly amongst the top quartile of funds within Morningstar\u00e2\u0080\u0099s Moderate Allocation category.",
      "url": "https://finnhub.io/api/news?id=af9090335462de0ade490b12852e111498cc7938f55c80e909064d6a99404ca0"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-06-12",
      "description": "xslF345X05/wk-form4_1749760336.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000156/xslF345X05/wk-form4_1749760336.xml"
    },
    {
      "form": "4",
      "date": "2025-06-12",
      "description": "xslF345X05/wk-form4_1749760229.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000154/xslF345X05/wk-form4_1749760229.xml"
    },
    {
      "form": "8-K",
      "date": "2025-06-10",
      "description": "jnj-20250610.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000152/jnj-20250610.htm"
    },
    {
      "form": "13F-HR",
      "date": "2025-05-07",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445425000238/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "4",
      "date": "2025-05-05",
      "description": "xslF345X05/wk-form4_1746479407.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000143/xslF345X05/wk-form4_1746479407.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}